Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.

Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL.

J Clin Oncol. 2006 Jul 20;24(21):3431-7.

PMID:
16849758
2.

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR.

J Clin Oncol. 2008 Sep 1;26(25):4189-99. doi: 10.1200/JCO.2007.11.5964. Review.

3.

Molecular genetic markers as predictors of response to chemotherapy in gliomas.

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K.

Curr Opin Oncol. 2007 Nov;19(6):606-11. Review.

PMID:
17906460
4.

[Resent advances in chemotherapy for malignant brain tumors].

Shibui S.

Gan To Kagaku Ryoho. 2005 Apr;32(4):442-7. Review. Japanese.

PMID:
15853207
5.

O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Silber JR, Bobola MS, Blank A, Chamberlain MC.

Biochim Biophys Acta. 2012 Aug;1826(1):71-82. doi: 10.1016/j.bbcan.2011.12.004. Epub 2012 Jan 8. Review.

6.

Epigenetic silencing of the MGMT gene in cancer.

Soejima H, Zhao W, Mukai T.

Biochem Cell Biol. 2005 Aug;83(4):429-37. Review.

PMID:
16094446
7.

Targeted modulation of MGMT: clinical implications.

Liu L, Gerson SL.

Clin Cancer Res. 2006 Jan 15;12(2):328-31. Review.

8.

Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis.

Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K.

Anticancer Res. 2009 Oct;29(10):3759-68. Review.

9.

[MGMT analysis in gliomas].

Quillien V, Vauléon E, Saikali S, Lesimple T, Hamlat A, Etcheverry A, Mosser J.

Bull Cancer. 2011 Mar;98(3):291-303. doi: 10.1684/bdc.2011.1332. Review. French.

10.

O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.

Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G.

Cell Death Dis. 2013 Oct 24;4:e876. doi: 10.1038/cddis.2013.388. Review.

11.

[Study on MGMT assay and tumor individual predictable chemotherapy].

Zhang YP.

Ai Zheng. 2004 Jun;23(6):724-34. Review. Chinese.

PMID:
15191682
12.

MGMT promoter methylation in malignant gliomas.

Riemenschneider MJ, Hegi ME, Reifenberger G.

Target Oncol. 2010 Sep;5(3):161-5. doi: 10.1007/s11523-010-0153-6. Epub 2010 Aug 20. Review.

PMID:
20725792
13.

[Gene MGMT and oligodendrogliomas. Fundamental data and short review of the literature].

Blanc JL, Wager M, Karrayan-Tapon L, Larsen CJ, Bataille B, Lapierre F.

Neurochirurgie. 2005 Sep;51(3-4 Pt 2):269-72. Review. French.

PMID:
16292171
14.

The role of integrins in glioma biology and anti-glioma therapies.

Tabatabai G, Tonn JC, Stupp R, Weller M.

Curr Pharm Des. 2011;17(23):2402-10. Review.

PMID:
21827415
15.

Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas.

Grossman SA.

Semin Oncol. 2003 Dec;30(6 Suppl 19):19-22. Review.

PMID:
14765380
16.

[Clinical trial updates for malignant brain tumors].

Wakabayashi T.

Rinsho Shinkeigaku. 2011 Nov;51(11):853-6. Review. Japanese.

PMID:
22277391
17.

Genetic alterations and chemotherapeutic response in human diffuse gliomas.

Kitange GJ, Smith JS, Jenkins RB.

Expert Rev Anticancer Ther. 2001 Dec;1(4):595-605. Review.

PMID:
12113092
18.

Molecular diagnostics of gliomas: the clinical perspective.

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.

Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23. Review.

PMID:
20862485
19.

The impact of extent of resection in the management of malignant gliomas of childhood.

Finlay JL, Wisoff JH.

Childs Nerv Syst. 1999 Nov;15(11-12):786-8. Review.

PMID:
10603023
20.

Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.

Srivenugopal KS, Rawat A, Niture SK, Paranjpe A, Velu C, Venugopal SN, Madala HR, Basak D, Punganuru SR.

Mini Rev Med Chem. 2016;16(6):455-64. Review.

PMID:
26202203

Supplemental Content

Support Center